137 related articles for article (PubMed ID: 24670803)
1. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases.
Xie JH; Yamniuk AP; Borowski V; Kuhn R; Susulic V; Rex-Rabe S; Yang X; Zhou X; Zhang Y; Gillooly K; Brosius R; Ravishankar R; Waggie K; Mink K; Price L; Rehfuss R; Tamura J; An Y; Cheng L; Abramczyk B; Ignatovich O; Drew P; Grant S; Bryson JW; Suchard S; Salter-Cid L; Nadler S; Suri A
J Immunol; 2014 May; 192(9):4083-92. PubMed ID: 24670803
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
Early GS; Zhao W; Burns CM
J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
[TBL] [Abstract][Full Text] [Related]
3. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
Shock A; Burkly L; Wakefield I; Peters C; Garber E; Ferrant J; Taylor FR; Su L; Hsu YM; Hutto D; Amirkhosravi A; Meyer T; Francis J; Malcolm S; Robinson M; Brown D; Shaw S; Foulkes R; Lawson A; Harari O; Bourne T; Maloney A; Weir N
Arthritis Res Ther; 2015 Sep; 17(1):234. PubMed ID: 26335795
[TBL] [Abstract][Full Text] [Related]
4. The role of CD40 in CD40L- and antibody-mediated platelet activation.
Langer F; Ingersoll SB; Amirkhosravi A; Meyer T; Siddiqui FA; Ahmad S; Walker JM; Amaya M; Desai H; Francis JL
Thromb Haemost; 2005 Jun; 93(6):1137-46. PubMed ID: 15968400
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice.
Robles-Carrillo L; Meyer T; Hatfield M; Desai H; Dávila M; Langer F; Amaya M; Garber E; Francis JL; Hsu YM; Amirkhosravi A
J Immunol; 2010 Aug; 185(3):1577-83. PubMed ID: 20585032
[TBL] [Abstract][Full Text] [Related]
6. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
[TBL] [Abstract][Full Text] [Related]
7. Platelet pro-aggregatory effects of CD40L monoclonal antibody.
Mirabet M; Barrabés JA; Quiroga A; Garcia-Dorado D
Mol Immunol; 2008 Feb; 45(4):937-44. PubMed ID: 17959249
[TBL] [Abstract][Full Text] [Related]
8. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge.
Ferrant JL; Benjamin CD; Cutler AH; Kalled SL; Hsu YM; Garber EA; Hess DM; Shapiro RI; Kenyon NS; Harlan DM; Kirk AD; Burkly LC; Taylor FR
Int Immunol; 2004 Nov; 16(11):1583-94. PubMed ID: 15466914
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a novel anti-rat CD40L antibody with inhibitory activities in vitro and in vivo.
Stax AM; Gelderman KA; Kamerling SW; van der Geest R; Schlagwein N; van Kooten C
J Immunol Methods; 2008 Jun; 335(1-2):46-52. PubMed ID: 18384807
[TBL] [Abstract][Full Text] [Related]
11. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Buhlman J; Xu J; Flavell RA; Korngold R; Noelle R; Vallera DA
J Immunol; 1997 Jan; 158(1):29-39. PubMed ID: 8977172
[TBL] [Abstract][Full Text] [Related]
12. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of pathogenic IgG autoantibody production in CD40L gene-deleted lupus-prone New Zealand Black mice.
Pau E; Chang NH; Loh C; Lajoie G; Wither JE
Clin Immunol; 2011 May; 139(2):215-27. PubMed ID: 21414847
[TBL] [Abstract][Full Text] [Related]
14. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.
Alvarez E; Moga E; Barquinero J; Sierra J; Briones J
Gene Ther; 2010 Apr; 17(4):469-77. PubMed ID: 20010627
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
Zhang X; Olsen HS; Chen S; So E; Zhou H; Burch E; Mérigeon EY; Block DS; Strome SE
J Immunol; 2016 Feb; 196(3):1165-76. PubMed ID: 26695368
[TBL] [Abstract][Full Text] [Related]
16. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism.
Nakamura M; Tanaka Y; Satoh T; Kawai M; Hirakata M; Kaburaki J; Kawakami Y; Ikeda Y; Kuwana M
Rheumatology (Oxford); 2006 Feb; 45(2):150-6. PubMed ID: 16188945
[TBL] [Abstract][Full Text] [Related]
17. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.
Sun W; Wang Q; Zhang L; Liu Y; Zhang M; Wang C; Wang J; Cao X
Transplantation; 2003 Nov; 76(9):1351-9. PubMed ID: 14627915
[TBL] [Abstract][Full Text] [Related]
18. Functional expression of chimeric Fab of an anti-CD40L mAb: Vector design and culture condition optimization.
Ge Y; Chen Y; Ju S; Zhang XG
Biomed Pharmacother; 2011 Feb; 65(1):52-9. PubMed ID: 21036518
[TBL] [Abstract][Full Text] [Related]
19. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.
Karpusas M; Lucci J; Ferrant J; Benjamin C; Taylor FR; Strauch K; Garber E; Hsu YM
Structure; 2001 Apr; 9(4):321-9. PubMed ID: 11525169
[TBL] [Abstract][Full Text] [Related]
20. Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model.
Ujiie H; Shibaki A; Nishie W; Shinkuma S; Moriuchi R; Qiao H; Shimizu H
Clin Immunol; 2012 Feb; 142(2):167-75. PubMed ID: 22044750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
